{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:36Z","timestamp":1790109936087,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prolactinomas are often treated initially with dopamine agonists (DA). For patients subsequently treated with surgery, the effect of cabergoline (CAB) on tumor fibrosis and its potential impact on surgical outcomes is largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Records of patients with prolactinoma treated by a single surgeon between 2006 and 2024 were examined. Analyses considered relationships among duration and cumulative dose of presurgical DA (DA\u2009+\u2009vs. DA-), extent of fibrosis measured quantitatively by collagen volume fraction (CVF) and qualitatively by surgeon assessment, and remission status at last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 59 patients, 22 were DA- and 37 were DA+, including 29 treated only with CAB and 8 treated with CAB and bromocriptine. There were 44 macroadenomas, 13 microadenomas, and 2 giant adenomas; 28 had cavernous sinus invasion (Knosp grade 3\u20134) 52.5% were in remission at last follow-up. Median cumulative CAB dose was 79.3\u00a0mg (range, 5.4\u20136711), used for a median duration of 570 days (range, 16-7830). Neither CAB dose nor duration correlated with CVF (r\n                      <jats:sup>2<\/jats:sup>\n                      \u2009&lt;\u20090.01, p\u2009=\u2009NS). Both surgeon fibrosis assessment and CVF were higher in DA\u2009+\u2009patients, but neither independently predicted remission. Cumulative CAB dose and duration also did not predict remission. On univariable analysis, cavernous sinus invasion (OR 10.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and tumor size (OR 6.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) predicted remission, but in multivariable analysis no single factor remained significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Duration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01628-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:19:20Z","timestamp":1768231160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-6431","authenticated-orcid":false,"given":"Adam N.","family":"Mamelak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Ben-Shlomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artak","family":"Labadzhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Bonert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33:101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/js.2017-00038","volume":"1","author":"AC Paepegaey","year":"2017","unstructured":"Paepegaey AC, Salenave S, Kamenicky P, Maione L, Brailly-Tabard S, Young J, Chanson P (2017) Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc 1:221\u2013230. https:\/\/doi.org\/10.1210\/js.2017-00038","journal-title":"J Endocr Soc"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1210\/jcem.85.9.6798","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053\u20133057. https:\/\/doi.org\/10.1210\/jcem.85.9.6798","journal-title":"J Clin Endocrinol Metab"},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904\u20139. https:\/\/doi.org\/10.1056\/NEJM199410063311403","journal-title":"N Engl J Med"},{"key":"1628_CR6","first-page":"753","volume":"24","author":"V Pascal-Vigneron","year":"1995","unstructured":"Pascal-Vigneron V, Weryha G, Bosc M, Leclere J (1995) [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study]. Presse Med 24:753\u20137","journal-title":"Presse Med"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EO-21-0038","volume":"2","author":"SMC De Sousa","year":"2022","unstructured":"De Sousa SMC (2022) Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr Oncol 2:R31\u2013R50. https:\/\/doi.org\/10.1530\/EO-21-0038","journal-title":"Endocr Oncol"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ando.2020.12.008","volume":"82","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T (2021) The risks of medical treatment of prolactinoma. Ann Endocrinol (Paris) 82:15\u201319. https:\/\/doi.org\/10.1016\/j.ando.2020.12.008","journal-title":"Ann Endocrinol (Paris)"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab 105:e32\u201341. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","volume":"185","author":"B Baussart","year":"2021","unstructured":"Baussart B, Villa C, Jouinot A, Raffin-Sanson ML, Foubert L, Cazabat L, Bernier M, Bonnet F, Dohan A, Bertherat J, Assie G, Gaillard S (2021) Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol 185:783\u2013791. https:\/\/doi.org\/10.1530\/EJE-21-0293","journal-title":"Eur J Endocrinol"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s40618-021-01569-6","volume":"44","author":"L Andereggen","year":"2021","unstructured":"Andereggen L, Frey J, Andres RH, Luedi MM, El-Koussy M, Widmer HR, Beck J, Mariani L, Seiler RW, Christ E (2021) First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest 44:2621\u20132633. https:\/\/doi.org\/10.1007\/s40618-021-01569-6","journal-title":"J Endocrinol Invest"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Quinones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14:68\u201374. https:\/\/doi.org\/10.1007\/s11102-010-0261-4","journal-title":"Pituitary"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00701-024-06198-5","volume":"166","author":"A Ryba","year":"2024","unstructured":"Ryba A, Gonzalez Lopez D, Rotermund R, Flitsch J (2024) Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients. Acta Neurochir (Wien) 166:316. https:\/\/doi.org\/10.1007\/s00701-024-06198-5","journal-title":"Acta Neurochir (Wien)"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1055\/s-0044-1786740","volume":"85","author":"IL Pecorari","year":"2024","unstructured":"Pecorari IL, Qama E, Akbar N, Colley P, Fang CH, Agarwal V (2024) The effect of preoperative Cabergoline on prolactinoma fibrosis: a case series. J Neurol Surg Rep 85:e66\u2013e73. https:\/\/doi.org\/10.1055\/s-0044-1786740","journal-title":"J Neurol Surg Rep"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ejendo\/lvae055","volume":"190","author":"D Zhang","year":"2024","unstructured":"Zhang D, Hugo W, Bergsneider M, Wang MB, Kim W, Han K, Vinters HV, Heaney AP (2024) Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis. Eur J Endocrinol 190:467\u2013478. https:\/\/doi.org\/10.1093\/ejendo\/lvae055","journal-title":"Eur J Endocrinol"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1210\/clinem\/dgad758","volume":"109","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shou X, Ji L, Cheng H, Shen M, Ma Z, He W, Ye Z, Zhang Y, Qiao N, Zhang Q, Wang Y (2024) Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases. J Clin Endocrinol Metab 109:1433\u20131442. https:\/\/doi.org\/10.1210\/clinem\/dgad758","journal-title":"J Clin Endocrinol Metab"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"bcr2017220971,-","DOI":"10.1136\/bcr-2017-220971","volume":"2017","author":"N Mohan","year":"2017","unstructured":"Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT (2017) Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case Rep 2017:bcr2017220971,-bcr-2017-220971. https:\/\/doi.org\/10.1136\/bcr-2017-220971","journal-title":"BMJ Case Rep"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12020-021-02744-8","volume":"74","author":"K Wright","year":"2021","unstructured":"Wright K, Lee M, Escobar N, Pacione D, Young M, Fatterpekar G, Agrawal N (2021) Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas. Endocrine 74:138\u2013145. https:\/\/doi.org\/10.1007\/s12020-021-02744-8","journal-title":"Endocrine"},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2019.3.JNS19121","volume":"133","author":"WT Burke","year":"2020","unstructured":"Burke WT, Penn DL, Castlen JP, Donoho DA, Repetti CS, Iuliano S, Barkhoudarian G, Laws ER (2020) Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 133:321\u2013328. https:\/\/doi.org\/10.3171\/2019.3.JNS19121","journal-title":"J Neurosurg"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fendo.2020.00439","volume":"11","author":"G Zielinski","year":"2020","unstructured":"Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P (2020) Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front Endocrinol (Lausanne) 11:439. https:\/\/doi.org\/10.3389\/fendo.2020.00439","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11102-021-01168-x","volume":"24","author":"JY Park","year":"2021","unstructured":"Park JY, Choi W, Hong AR, Yoon JH, Kim HK, Jang WY, Jung S, Kang HC (2021) Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary 24:955\u2013963. https:\/\/doi.org\/10.1007\/s11102-021-01168-x","journal-title":"Pituitary"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ando.2021.11.008","volume":"83","author":"H Lasolle","year":"2022","unstructured":"Lasolle H, Teulade M, Lapras V, Vasiljevic A, Borson-Chazot F, Jouanneau E, Raverot G (2022) Postoperative remission of non-invasive lactotroph pituitary tumor: a single-center experience. Ann Endocrinol (Paris) 83:1\u20138. https:\/\/doi.org\/10.1016\/j.ando.2021.11.008","journal-title":"Ann Endocrinol (Paris)"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko AS, Wohrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122:803\u2013811. https:\/\/doi.org\/10.3171\/2014.12.JNS141083","journal-title":"J Neurosurg"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/17446651.2022.2131531","volume":"17","author":"A Mamelak","year":"2022","unstructured":"Mamelak A (2022) Surgery as a first-line option for prolactinomas. Expert Rev Endocrinol Metab 17:485\u2013498. https:\/\/doi.org\/10.1080\/17446651.2022.2131531","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3171\/2020.4.JNS193288","volume":"134","author":"MJ Rutkowski","year":"2021","unstructured":"Rutkowski MJ, Chang KE, Cardinal T, Du R, Tafreshi AR, Donoho DA, Brunswick A, Micko A, Liu CJ, Shiroishi MS, Carmichael JD, Zada G (2021) Development and clinical validation of a grading system for pituitary adenoma consistency. J Neurosurg 134:1800\u20131807. https:\/\/doi.org\/10.3171\/2020.4.JNS193288","journal-title":"J Neurosurg"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","volume":"154","author":"K Wright","year":"2021","unstructured":"Wright K, Chaker L, Pacione D, Sam K, Feelders R, Xia Y, Agrawal N (2021) Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg 154:e349\u2013e369. https:\/\/doi.org\/10.1016\/j.wneu.2021.07.035","journal-title":"World Neurosurg"},{"key":"1628_CR27","unstructured":"R Core Team\u00a0(2022) R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. Available from: https:\/\/www.R-project.org\/"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40618-025-02559-8","volume":"48","author":"M Detomas","year":"2025","unstructured":"Detomas M, Altieri B, Nasi-Kordhishti I, Ryba A, Haberbosch L, Chierigo F, Deutschbein T, Fassnacht M, Mortini P, Flitsch J, Honegger J, Losa M (2025) Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study. J Endocrinol Invest 48:1363\u20131370. https:\/\/doi.org\/10.1007\/s40618-025-02559-8","journal-title":"J Endocrinol Invest"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"9930059","DOI":"10.1155\/2021\/9930059","volume":"2021","author":"J Lu","year":"2021","unstructured":"Lu J, Cai L, Wu Z, Lin W, Xu J, Zhu Z, Wang C, Li Q, Su Z (2021) Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis. Int J Endocrinol 2021:9930059. https:\/\/doi.org\/10.1155\/2021\/9930059","journal-title":"Int J Endocrinol"},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","volume":"8","author":"ME Molitch","year":"2005","unstructured":"Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43\u201352. https:\/\/doi.org\/10.1007\/s11102-005-5085-2","journal-title":"Pituitary"},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11102-023-01301-y","volume":"26","author":"A Ben-Shlomo","year":"2023","unstructured":"Ben-Shlomo A (2023) Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis. Pituitary 26:263\u2013265. https:\/\/doi.org\/10.1007\/s11102-023-01301-y","journal-title":"Pituitary"},{"key":"1628_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153570","author":"A Papait","year":"2022","unstructured":"Papait A, Romoli J, Stefani FR, Chiodelli P, Montresor MC, Agoni L, Silini AR, Parolini O (2022) Fight the cancer, hit the CAF! Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14153570","journal-title":"Cancers (Basel)"},{"key":"1628_CR33","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1210\/en.2005-0430","volume":"146","author":"DK Sarkar","year":"2005","unstructured":"Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI, Chen CP (2005) Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 146:4179\u20134188. https:\/\/doi.org\/10.1210\/en.2005-0430","journal-title":"Endocrinology"},{"key":"1628_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/02688690802617046","volume":"23","author":"H Wang","year":"2009","unstructured":"Wang H, Li W, Shi D, Ye Z, Qin F, Guo Y, Yuan X (2009) Expression of TGFbeta1 and pituitary adenoma fibrosis. Br J Neurosurg 23:293\u2013296. https:\/\/doi.org\/10.1080\/02688690802617046","journal-title":"Br J Neurosurg"},{"key":"1628_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.brainres.2018.07.024","volume":"1698","author":"B Hu","year":"2018","unstructured":"Hu B, Mao Z, Jiang X, He D, Wang Z, Wang X, Zhu Y, Wang H (2018) Role of TGF-beta1\/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma. Brain Res 1698:204\u2013212. https:\/\/doi.org\/10.1016\/j.brainres.2018.07.024","journal-title":"Brain Res"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"e1796","DOI":"10.1210\/clinem\/dgae090","volume":"109","author":"AN Mamelak","year":"2024","unstructured":"Mamelak AN (2024) Between a rock and a hard place: the role of DA-induced tumor fibrosis in prolactinoma management. J Clin Endocrinol Metab 109:e1796\u2013e1797. https:\/\/doi.org\/10.1210\/clinem\/dgae090","journal-title":"J Clin Endocrinol Metab"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"e1833","DOI":"10.1210\/clinem\/dgae652","volume":"110","author":"VR van Trigt","year":"2025","unstructured":"van Trigt VR, Bakker LEH, Pelsma ICM, Zandbergen IM, Jentus MM, Kruit MC, Dekkers OM, van Furth WR, Verstegen MJT, Biermasz NR, Dutch Prolactinoma Study, G. (2025) The changing treatment paradigm for prolactinoma-a prospective series of 100 consecutive neurosurgical cases. J Clin Endocrinol Metab 110:e1833\u2013e1844. https:\/\/doi.org\/10.1210\/clinem\/dgae652","journal-title":"J Clin Endocrinol Metab"},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651\u2013662. https:\/\/doi.org\/10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"},{"key":"1628_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11102-008-0135-1","volume":"12","author":"ME Sughrue","year":"2009","unstructured":"Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr. (2009) Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12:158\u2013164. https:\/\/doi.org\/10.1007\/s11102-008-0135-1","journal-title":"Pituitary"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11102-022-01221-3","volume":"25","author":"H Abou-Al-Shaar","year":"2022","unstructured":"Abou-Al-Shaar H, Mallela AN, Patel A, Shariff RK, Shin SS, Choi PA, Faraji AH, Fazeli PK, Costacou T, Wang EW, Fernandez-Miranda JC, Snyderman CH, Gardner PA, Zenonos GA (2022) The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus. Pituitary 25:508\u2013519. https:\/\/doi.org\/10.1007\/s11102-022-01221-3","journal-title":"Pituitary"}],"updated-by":[{"DOI":"10.1007\/s11102-026-01734-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000}}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01628-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01628-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01628-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:51:17Z","timestamp":1787503877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01628-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01628-8","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised and correct author name \"Anat Ben-Shlomo\" has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11102-026-01734-1","URL":"https:\/\/doi.org\/10.1007\/s11102-026-01734-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}